Compare $ALGS vs $CVM | Chartloom

Compare

$ALGS vs $CVM

Aligos Therapeutics Inc · CEL-SCI Corp

ALGS

Aligos Therapeutics Inc

CVM

CEL-SCI Corp

Compare $ALGS vs $CVM

Comparing Aligos Therapeutics Inc and CEL-SCI Corp

ALGSAligos Therapeutics Inc

CVMCEL-SCI Corp

ALGSAligos Therapeutics Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.83x

Rev growth (TTM)

893.0%

YTD performance

-41.5%

52W performance

-46.2%

FCF yield

-286.0%

CVMCEL-SCI Corp

Market cap

$34M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-62.3%

52W performance

-80.7%

FCF yield

-49.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALGS

CVM

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

CVM

CEL-SCI Corp

Market Cap

ALGS$33M

CVM$34M

Enterprise Value

ALGS$3M

CVM$34M

Price

ALGS$5.34

CVM$1.94

P/E Ratio

ALGSN/A

CVMN/A

P/S Ratio

ALGS1.05x

CVM72.73x

EV/Sales

ALGS0.09x

CVM72.27x

EV/EBITDA

ALGS0.00x

CVM0.00x

P/B Ratio

ALGS1.09x

CVM3.71x

P/FCF Ratio

ALGSN/A

CVMN/A

EV/FCF

ALGS-0.03x

CVM-2.01x

PEG Ratio

ALGSN/A

CVMN/A

Forward P/E (NTM)

ALGSN/A

CVMN/A

Forward P/S (NTM)

ALGS4.83x

CVMN/A

Revenue (TTM)

ALGS$32M

CVM$0

Revenue Growth (YoY)

ALGS893.0%

CVMN/A

Forward Rev Growth

ALGS-84.9%

CVM0.0%

Gross Margin (TTM)

ALGS0.0%

CVM0.0%

Operating Margin (TTM)

ALGS0.0%

CVM0.0%

EBITDA Margin (TTM)

ALGS-247.2%

CVM0.0%

Net Margin (TTM)

ALGS-241.0%

CVM0.0%

FCF Margin (TTM)

ALGS-299.9%

CVMN/A

Net Income (TTM)

ALGS$-76M

CVM$-23M

FCF (TTM)

ALGS$-95M

CVM$-17M

EPS (TTM)

ALGS-$7.28

CVM-$1.87

ROE (TTM)

ALGS-16072.0%

CVM-20214.0%

ROA (TTM)

ALGS-9230.0%

CVM-10078.0%

ROIC (TTM)

ALGS-16035.0%

CVM-12370.0%

Cash

ALGS$30M

CVM$7M

Debt

ALGS$64K

CVM$6M

Net Cash/Debt

ALGS$30M

CVM$256K

Current Ratio (TTM)

ALGS2.19x

CVM1.48x

Quick Ratio (TTM)

ALGS2.19x

CVM1.29x

Debt/Equity (TTM)

ALGS0.00x

CVM0.57x

Debt/Assets (TTM)

ALGS0.0%

CVM0.0%

Interest Coverage (TTM)

ALGSN/A

CVMN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

CVM0.00x

Beta

ALGS2.48

CVM0.62

52W Performance

ALGS-46.2%

CVM-80.7%

YTD Performance

ALGS-41.5%

CVM-62.3%

% from 52W High

ALGS-61.0%

CVM-81.3%

% from 52W Low

ALGS34.2%

CVM118.0%

Asset Turnover (TTM)

ALGS0.38x

CVM0.01x

FCF Yield (TTM)

ALGS-286.0%

CVM-49.4%

Earnings Yield (TTM)

ALGS-229.8%

CVM-67.0%

Dividend Yield (TTM)

ALGSN/A

CVMN/A

Rule of 40

ALGS593.1

CVM0.0

EV/GP/RG

ALGSN/A

CVMN/A

Ticker research

View ALGS research View CVM research

Metric	ALGS Aligos Therapeutics Inc	CVM CEL-SCI Corp
Market & Valuation
Market Cap	$33M	$34M
Enterprise Value	$3M	$34M
Price	$5.34	$1.94
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	72.73x
EV/Sales	0.09x	72.27x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	3.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	-2.01x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-23M
FCF (TTM)	$-95M	$-17M
EPS (TTM)	-$7.28	-$1.87
ROE (TTM)	-16072.0%	-20214.0%
ROA (TTM)	-9230.0%	-10078.0%
ROIC (TTM)	-16035.0%	-12370.0%
Financial Health
Cash	$30M	$7M
Debt	$64K	$6M
Net Cash/Debt	$30M	$256K
Current Ratio (TTM)	2.19x	1.48x
Quick Ratio (TTM)	2.19x	1.29x
Debt/Equity (TTM)	0.00x	0.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	0.62
52W Performance	-46.2%	-80.7%
YTD Performance	-41.5%	-62.3%
% from 52W High	-61.0%	-81.3%
% from 52W Low	34.2%	118.0%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.01x
FCF Yield (TTM)	-286.0%	-49.4%
Earnings Yield (TTM)	-229.8%	-67.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View CVM research

Valuation

P/S Ratio

ALGS

1.05x

CVM

72.73x

EV/FCF

CVM

-2.01x

ALGS

-0.03x

Growth & revenue

Revenue Growth TTM

ALGS

893.0%

Forward Revenue Growth

CVM

0.0%

ALGS

-84.9%

Profitability & performance

Gross Margin

ALGS

0.0%

CVM

0.0%

ROE

ALGS

-16072.0%

CVM

-20214.0%

FCF Yield %

CVM

-49.4%

ALGS

-286.0%

52-Week Performance

ALGS

-46.2%

CVM

-80.7%

Detailed metrics comparison

ALGS

Aligos Therapeutics Inc

CVM

CEL-SCI Corp

Market Cap

ALGS$33M

CVM$34M

Enterprise Value

ALGS$3M

CVM$34M

Price

ALGS$5.34

CVM$1.94

P/E Ratio

ALGSN/A

CVMN/A

P/S Ratio

ALGS1.05x

CVM72.73x

EV/Sales

ALGS0.09x

CVM72.27x

EV/EBITDA

ALGS0.00x

CVM0.00x

P/B Ratio

ALGS1.09x

CVM3.71x

P/FCF Ratio

ALGSN/A

CVMN/A

EV/FCF

ALGS-0.03x

CVM-2.01x

PEG Ratio

ALGSN/A

CVMN/A

Forward P/E (NTM)

ALGSN/A

CVMN/A

Forward P/S (NTM)

ALGS4.83x

CVMN/A

Revenue (TTM)

ALGS$32M

CVM$0

Revenue Growth (YoY)

ALGS893.0%

CVMN/A

Forward Rev Growth

ALGS-84.9%

CVM0.0%

Gross Margin (TTM)

ALGS0.0%

CVM0.0%

Operating Margin (TTM)

ALGS0.0%

CVM0.0%

EBITDA Margin (TTM)

ALGS-247.2%

CVM0.0%

Net Margin (TTM)

ALGS-241.0%

CVM0.0%

FCF Margin (TTM)

ALGS-299.9%

CVMN/A

Net Income (TTM)

ALGS$-76M

CVM$-23M

FCF (TTM)

ALGS$-95M

CVM$-17M

EPS (TTM)

ALGS-$7.28

CVM-$1.87

ROE (TTM)

ALGS-16072.0%

CVM-20214.0%

ROA (TTM)

ALGS-9230.0%

CVM-10078.0%

ROIC (TTM)

ALGS-16035.0%

CVM-12370.0%

Cash

ALGS$30M

CVM$7M

Debt

ALGS$64K

CVM$6M

Net Cash/Debt

ALGS$30M

CVM$256K

Current Ratio (TTM)

ALGS2.19x

CVM1.48x

Quick Ratio (TTM)

ALGS2.19x

CVM1.29x

Debt/Equity (TTM)

ALGS0.00x

CVM0.57x

Debt/Assets (TTM)

ALGS0.0%

CVM0.0%

Interest Coverage (TTM)

ALGSN/A

CVMN/A

Net Debt/EBITDA (TTM)

ALGS0.00x

CVM0.00x

Beta

ALGS2.48

CVM0.62

52W Performance

ALGS-46.2%

CVM-80.7%

YTD Performance

ALGS-41.5%

CVM-62.3%

% from 52W High

ALGS-61.0%

CVM-81.3%

% from 52W Low

ALGS34.2%

CVM118.0%

Asset Turnover (TTM)

ALGS0.38x

CVM0.01x

FCF Yield (TTM)

ALGS-286.0%

CVM-49.4%

Earnings Yield (TTM)

ALGS-229.8%

CVM-67.0%

Dividend Yield (TTM)

ALGSN/A

CVMN/A

Rule of 40

ALGS593.1

CVM0.0

EV/GP/RG

ALGSN/A

CVMN/A

Ticker research

View ALGS research View CVM research

Metric	ALGS Aligos Therapeutics Inc	CVM CEL-SCI Corp
Market & Valuation
Market Cap	$33M	$34M
Enterprise Value	$3M	$34M
Price	$5.34	$1.94
P/E Ratio	N/A	N/A
P/S Ratio	1.05x	72.73x
EV/Sales	0.09x	72.27x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.09x	3.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.03x	-2.01x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.83x	N/A
Revenue & Growth
Revenue (TTM)	$32M	$0
Revenue Growth (YoY)	893.0%	N/A
Forward Rev Growth	-84.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-247.2%	0.0%
Net Margin (TTM)	-241.0%	0.0%
FCF Margin (TTM)	-299.9%	N/A
Net Income (TTM)	$-76M	$-23M
FCF (TTM)	$-95M	$-17M
EPS (TTM)	-$7.28	-$1.87
ROE (TTM)	-16072.0%	-20214.0%
ROA (TTM)	-9230.0%	-10078.0%
ROIC (TTM)	-16035.0%	-12370.0%
Financial Health
Cash	$30M	$7M
Debt	$64K	$6M
Net Cash/Debt	$30M	$256K
Current Ratio (TTM)	2.19x	1.48x
Quick Ratio (TTM)	2.19x	1.29x
Debt/Equity (TTM)	0.00x	0.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.48	0.62
52W Performance	-46.2%	-80.7%
YTD Performance	-41.5%	-62.3%
% from 52W High	-61.0%	-81.3%
% from 52W Low	34.2%	118.0%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.01x
FCF Yield (TTM)	-286.0%	-49.4%
Earnings Yield (TTM)	-229.8%	-67.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	593.1	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALGS research	View CVM research